AHA Coding Clinic® for HCPCS - 2016 Quarter 4; For Your Information
Medicare reporting guidance for Mitomycin
Medicare has provided the following instruction for hospital outpatient departments for the reporting of HCPCS code J7315 , Mitomycin, ophthalmic, 0.2 mg, or HCPCS code J7999 , Compounded drug, not otherwise classified, for the topical application of Mitomycin during or following ophthalmic surgery. Hospitals may report HCPCS code J7315 only if the hospital uses Mitomycin with the trade name Mitosol®. HCPCS code J7999 would be reported for any other topical Mitomycin. Additionally, hospitals are not permitted to report HCPCS code J9280 , Injection, mitomycin, 5 mg, for the topical application of Mitomycin. Please note: Other payers should be contacted regarding...
Subscribe or sign in to view the full article.
Article Overview
This article explains Medicare reporting guidance for hospital outpatient departments related to topical Mitomycin use during or after ophthalmic surgery. It is intended for hospital coders, billers, and revenue cycle staff who need to understand which HCPCS drug codes Medicare references and how the article frames payer-specific reporting considerations.
Why This Topic Matters
Hospitals need to align outpatient drug reporting with Medicare guidance and avoid applying the same approach across all payers without checking policy differences.
What You Will Learn
- How Medicare addresses outpatient hospital reporting for topical Mitomycin.
- Which billing considerations are tied to ophthalmic surgery contexts.
- Why payer-specific policies may need separate review.
- How the article frames HCPCS drug reporting options for hospital outpatient departments.
Who Should Read This
- Hospital outpatient coders
- Hospital billers
- Revenue cycle staff
- Compliance teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com